Hyodo Ichinosuke
Division of Gastroenterology, University of Tsukuba, Japan.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:64-7.
We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer. The treatment was repeated every 3 weeks. Twenty patients were studied. Dose-limiting toxicities of grade 3 diarrhea and stomatitis were observed in one patient at the dose of cisplatin 20 mg/m2. Grade 2 gastrointestinal adverse reactions, such as nausea and anorexia, were seen in approximately half of patients at this dose level within the first two treatment cycles. This was the maximum acceptable level. The overall response rate in 18 patients evaluated was 61%. The median survival was 11 months, despite including 11 pre-treated patients. S-1 given with weekly cisplatin was a feasible and promising combination regimen for an outpatient setting.
我们为转移性胃癌患者研发了一种联合化疗方案，包括静脉注射顺铂（第1天和第8天，每周给药一次），联合固定剂量（70mg/m²/天）的S-1（第1 - 14天）。每3周重复一次治疗。共研究了20例患者。在顺铂剂量为20mg/m²时，1例患者出现了3级腹泻和口腔炎的剂量限制性毒性。在该剂量水平下，约一半患者在前两个治疗周期内出现了2级胃肠道不良反应，如恶心和厌食。这是最大可接受水平。在评估的18例患者中，总体缓解率为61%。尽管纳入了11例经治患者，中位生存期仍为11个月。每周一次顺铂联合S-1是一种适用于门诊治疗的可行且有前景的联合方案。
